波那普令 | 20448-86-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 波那普令
• 中文别名: 宝纳普利；3-二乙氨基丙基2-苯基双环[2.2.1]庚烷-2-羧酸酯；波那普林
• 英文名称: Bornaprine
• 英文别名: 3-(diethylamino)propyl 2-phenylbicyclo[2.2.1]heptane-2-carboxylate
• CAS: 20448-86-6
• 化学式: C₂₁H₃₁NO₂
• 分子量: 329.5
• InChiKey: BDNMABJZSXTKAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  434.3±38.0 °C(Predicted)
• 密度：
  1.056±0.06 g/cm3(Predicted)
• 保留指数：
  2255

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS UTILISÉS COMME MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE DU GROUPE II
  申请人：MAVALON THERAPEUTICS LTD

  公开号：WO2018206820A1

  公开（公告）日：2018-11-15

  The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (la), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (la) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (la) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. The present invention further provides compounds of formula (I) or (la) that are modulators of metabotropic glutamate receptors (mGluRs), particularly positive allosteric modulators of mG!uRs, and more specifically positive allosteric modulators of mGluR3.

  本发明提供了一般式(I)的新颖杂环化合物，包括一般式(la)的新化合物，以及含有它们的药物组合物。此外，提供了一般式(I)或(la)的化合物和含有它们的药物组合物，用于治疗和/或预防与改变谷氨酸能信号和/或功能相关的疾病，以及那些可能受到哺乳动物谷氨酸水平或信号改变影响的疾病。一般式(I)或(la)的化合物可以作为对谷氨酸敏感的神经系统受体的调节剂，特别是代谢型谷氨酸受体(mGluRs)的调节剂，这使它们特别适用于治疗和/或预防急性和慢性神经和/或精神障碍。本发明还提供了一般式(I)或(la)的化合物，它们是代谢型谷氨酸受体(mGluRs)的调节剂，特别是mGluRs的正向变构调节剂，更具体地说是mGluR3的正向变构调节剂。
• [EN] RUBIDIUM AND/OR ZINC COMPOUNDS FOR TREATING PARKINSON'S AND OTHER NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS DE RUBIDIUM ET/OU DE ZINC POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON ET D'AUTRES MALADIES NEURODÉGÉNÉRATIVES
  申请人：VECTOR VITALE IP LLC

  公开号：WO2021071499A1

  公开（公告）日：2021-04-15

  Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula (1), below, wherein each of R1 through R14 is independently selected from H, OH, F, C1, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.

  含有盐、化合物和富集64Zn的锌的化合物，例如富集64Zn的天冬酸锌，以及进一步可能包括通式（1）所示的富集85Rb的铷盐化合物，其中R1至R14中的每个均独立选择自H、OH、F、C1、Br、I、C1-C6烷基、C1-C6烷氧基和NO2，例如通式1中R3为CH3且所有其他R基为H的化合物，用于治疗神经退行性疾病（NDD），如帕金森病（PD）。方法包括向患有NDD的患者施用这种组合物以治疗NDD，如PD，可以选择与其他用于治疗NDD（如PD）的任何其他治疗方法结合使用。
• [EN] COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2, 4-DIONES FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] POLYTHÉRAPIE UTILISANT DES 5-(BENZYL)-5-DEUTÉRO-THIAZOLIDINE-2,4-DIONES OXY-SUBSTITUÉES ÉNANTIOPURES, ENRICHIES EN DEUTÉRIUM POUR LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：DEUTERX LLC

  公开号：WO2016153948A1

  公开（公告）日：2016-09-29

  The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.

  这项发明提供了使用对映纯的富氘吡格列酮的联合疗法，以及使用该联合疗法治疗非酒精性脂肪性肝炎、糖尿病、纤维化疾病和其他疾病的药物组合和治疗方法。
• [EN] METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME<br/>[FR] PROCÉDÉS DE RÉDUCTION DE LA CONCENTRATION EN GLYCOSPHINGOLIPIDES DANS LE TISSU CÉRÉBRAL ET PROCÉDÉS DE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES IMPLIQUANT CES DERNIERS
  申请人：GENZYME CORP

  公开号：WO2022024062A1

  公开（公告）日：2022-02-03

  Provided are methods for treating or preventing Parkinson's disease or dementia with Lewy Bodies in a human subject. The methods target lipid dysregulation in brain tissue of the subject and can, in particular, reduce the concentration of glycosphingolipids in brain tissue. The methods use quinuclidine compounds of formula (I), or pharmaceutically acceptable prodrugs or salts thereof. In particular, the human subject may be a carrier of one or more glucocerebrosidase 1 gene (GBA1) mutations, e.g. a heterozygous carrier of GBA1 mutations. Also provided are methods for assessing the effectiveness of treatments as described herein.

  提供了一种治疗或预防人类患帕金森病或Lewy体痴呆的方法。该方法针对患者脑组织中的脂质失调，并可特别降低脑组织中的糖脂类浓度。该方法使用公式（I）的喹啉类化合物或其药学上可接受的前药或盐。特别地，人类受试者可能是一种或多种葡萄糖酸酰基酶1基因（GBA1）突变的携带者，例如GBA1突变的杂合携带者。此外，还提供了评估本文所述治疗方法有效性的方法。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。